CAR-T Cell Therapies Show Unprecedented Success in Targeting and Eliminating Tumors

  • Revolutionary cancer treatment harnessing the body's own immune cells
  • Significant tumor reduction in patients with certain types of leukemia and lymphoma
  • Potential to provide long-term remission and even cure certain cancers
Explore CART-T Cell Therapies

CAR-T cell therapies offered through our network are conducted in accredited international facilities that comply with local regulatory standards. These therapies may not be FDA-approved for certain conditions and should be pursued only after thorough consultation with your healthcare provider. Patients are advised to understand the risks, benefits, and regulatory status of CAR-T cell therapies in the country of treatment.

Clinicians International can help

Start your Free Pre-Consultation Now

Results and offers may vary.

Powered by the latest peer-reviewed research and the world’s best CART-T cells therapies specialists

In clinical trials, CAR-T cell therapies such as Kymriah (tisagenlecleucel) have shown remarkable success rates, with complete remission rates of around 83% in pediatric patients with acute lymphoblastic leukemia (ALL)
Yescarta (axicabtagene ciloleucel) has demonstrated sustained remission in patients with large B-cell lymphoma, with approximately 42% of patients remaining in remission three years post-treatment.

Are you a good candidate for CART-T Cells Therapies?

Start your Free Pre-Consultation Now

Specific Cancer Types
certain types of leukemia and lymphoma

/assets/Explore safe surgery options

CAR-T cell therapies are most effective in patients with certain types of cancers, such as B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL).

Refractory or Relapsed
cancer

/assets/Explore safe surgery options

Ideal candidates are patients whose cancer has not responded to standard treatments (refractory) or has returned after initial successful treatment (relapsed).

Adequate Health
to withstand therapy

/assets/Explore safe surgery options

Patients need to be in sufficient overall health to tolerate the rigorous CAR-T cell therapy process, including chemotherapy and potential side effects.

Prelimenary steps before
starting CART-T cells therapies

/assets/Free pre-consultation/assets/Free pre-consultation/assets/Free pre-consultation/assets/Free pre-consultation/assets/Free pre-consultation/assets/Free pre-consultation

24/7 access to free pre-consultation

Through Clinicians International, you can take a thorough pre-consultation and get matched with the world’s CART-T cells therapies centers to evaluate your options.

How it Works

Frequently asked Questions about car-t cell therapies

We believe safety is the first criteria when you cross borders to seek much needed care. We will have your back in making sure everything is following CDC guidelines for medical tourism and we will have your interest at heart at every step of the treatment to advocate for your rights as a patient around the world.
CAR-T cell therapy is mainly used to treat hematologic cancers such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma. Research is ongoing for its use in other cancers.
Risks include cytokine release syndrome (CRS), which can cause high fever and flu-like symptoms, neurotoxicity, and increased risk of infections. These side effects can be severe but are generally manageable with medical intervention.
The process involves collecting a patient’s T cells, genetically modifying them to express CARs, expanding these cells in the laboratory, and then infusing them back into the patient to attack cancer cells.
CAR-T cell therapy has shown high remission rates in patients with certain types of leukemia and lymphoma who have not responded to other treatments. However, its effectiveness can vary, and long-term outcomes are still being evaluated.

Hear it from research papers

CAR T-Cell Therapy for Cancer:

Latest Updates and Challenges - 2023

This paper discusses the latest updates and challenges in CAR-T cell therapy, with a focus on B-lymphoid malignancies and selected solid tumors, highlighting the biological mechanisms, clinical data, and future potential of this therapy.

Chimeric antigen receptor T cell

therapy for cancer - 2022

This review provides an overview of CAR-T cell therapy, focusing on its clinical applications, practical considerations for patient management, and the unique toxicities associated with the treatment.

The next-generation CAR-T

therapy landscape - 2023

his paper reviews the latest developments in CAR-T therapy, focusing on advancements, challenges, and the future direction of this innovative treatment for cancer.